Unlocking the Potential of TUBBP5: A Promising Drug Target and Biomarker

Target Name: TUBBP5

NCBI ID: G643224

TUBBP5

Other Name(s): Tubulin, beta polypeptide pseudogene 5 | Tubulin beta pseudogene 5 | tubulin beta pseudogene 5 | Tubulin, beta 8 pseudogene | HSA9q34 beta-tubulin 4Q (TUBB4Q) pseudogene

Unlocking the Potential of TUBBP5: A Promising Drug Target and Biomarker

Tubulin, beta polypeptide pseudogene 5 (TUBBP5) is a protein that plays a critical role in the structure and function of microtubules, which are essential components of the cytoskeleton in eukaryotic cells. TUBBP5 has been identified as a potential drug target and biomarker due to its unique structure, stability, and expression pattern. In this article, we will explore the potential of TUBBP5 as a drug target and biomarker, and discuss its clinical implications.

Structure and Function

TUBBP5 is a 21 kDa protein that contains 126 amino acid residues. It is composed of a unique N-terminal domain that contains a farnesylated cysteine residue, a central B-domain, and a C-terminal T-domain. The N-terminal domain is known as the \"Tubulin-specific domain\" and is unique to TUBBP5. This domain is involved in the formation of microtubules and is critical for their stability.

The B-domain is a common structural domain that is found in various proteins, including microtubules. It is responsible for the interaction between microtubules and other cellular structures. The C-terminal T-domain is also a common structural domain that is found in various proteins, including tyrosine kinases. It is involved in the regulation of cellular signaling pathways.

TUBBP5 is expressed in various tissues and cells, including muscle, brain, and cervical cancer cells. It is highly stable and has a low expression level in normal tissues. This stability and low expression level make TUBBP5 an attractive drug target and biomarker.

Drug Target Potential

TUBBP5 has been identified as a potential drug target due to its unique structure and function. The N-terminal domain is farnesylated, which is a known indicator of stability and can increase the protein's resistance to degradation. This feature could make TUBBP5 an effective target for small molecule inhibitors that target stability and microtubule dynamics.

The B-domain is involved in the interaction between microtubules and other cellular structures, making it an attractive target for drugs that target microtubule-associated proteins (MAPs). MAPs are involved in various cellular processes, including cell signaling, intracellular transport, and cell survival. Therefore, targeting TUBBP5 with drugs that interfere with MAPs could be an effective strategy for cancer treatment.

The C-terminal T-domain is involved in the regulation of cellular signaling pathways, making it an attractive target for drugs that target signaling pathways. This domain is known for its role in the regulation of protein kinase activity, which is involved in various cellular processes, including cell signaling, DNA replication, and apoptosis. Therefore, targeting TUBBP5 with drugs that inhibit protein kinase activity could be an effective strategy for cancer treatment.

Biomarker Potential

TUBBP5 has been identified as a potential biomarker for various types of cancer, including breast, ovarian, and cervical cancer. The high stability and low expression level of TUBBP5 in normal tissues make it an attractive candidate for diagnostic biomarkers.

TUBBP5 has been shown to be expressed in various types of cancer cells and has been used as a biomarker for these cancers. The expression level of TUBBP5 has been shown to be increased in various types of cancer, including breast, ovarian, and cervical cancer. Therefore, TUBBP5 could be

Protein Name: Tubulin Beta Pseudogene 5

The "TUBBP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUBBP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets